Archive for the ‘Health’ Category

Dahua Technology Launches Retail Epidemic Safety Protection Solution To Enhance Store Operation Safety Under COVID-19

KINGSTON, Jamaica, July 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — A recent report from AP News shows that a lot of major non-essential retailers worldwide have been affected by COVID-19. According to Neil Saunders, Managing Director of GlobalData Retail, more than 190,000 stores have temporarily closed, accounting for nearly 50% of U.S. retail square footage. At the same time, Swedish fashion retailer H&M also implied that after temporarily closing 3,441 of its 5,062 stores globally, it may be forced to lay off some employees permanently. How to survive during the pandemic and take effective prevention and control measures after work resumption has become a major consideration for retailers across the globe.

In response to the challenges facing the retail industry, Dahua Technology, a world-leading video-centric smart IoT solution and service provider, has launched a professional Retail Epidemic Safety Protection Solution to help retailers maintain safe operations and improve business efficiency during the pandemic, as well as providing upgraded plans to increase ROI after business resumption.

Featuring thermal body temperature monitoring and customer flow control, the Dahua Retail Epidemic Safety Protection Solution combines two technological advantages enabled by AI to provide double value for retailers, assisting in slowing the spread of the virus while creating a safe in-store shopping experience for customers.

The Dahua thermal body temperature monitoring camera allows highly accurate body temperature monitoring of ±0.3℃ (with blackbody). With built-in AI algorithm, it can simultaneously monitor a group of people from up to 3-meter distance, enabling fast and non-contact access. When installed at the entrances of supermarkets and shopping malls, it can help retailers with preliminary screening of employees and customers with abnormal body temperature. It notifies users to take corresponding measures before the temperatures change significantly, thereby enabling the appropriate protocol and conducting a second verification by medical professionals if necessary.

For retailers who require limited customer flow during the pandemic, the Dahua AI-empowered people counting camera can automatically and accurately calculate the real-time number of people entering the store, avoiding congestion and helping to mitigate the spread of the pandemic. When the number of shoppers exceeds the set value, the device will alarm and will display on the digital signage at the entrance of the store that the number of people inside is full, reminding customers to wait at the door. No extra employees are needed to count customers manually at the door, which can help retailers reduce labor costs and improve their management efficiency.

Excellent authorized store in Jamaica
Beauty Queen Plaza
13 Crane blvd Fairview Shopping Centre Montego Bay
Tel.: 876-631-7317

Photo - https://mma.prnewswire.com/media/1217051/Dahua_Technology.jpg

Click Here for More Information »

Religious Discrimination Is Hindering The COVID-19 Response

CaribPR Wire, Mon. July 20, 2020: Unintended pandemic-like consequences from the COVID-19 have been striking the globe. With the unclear root cause of the disease, minority groups have become the target of the blame with the spread of the crisis.

“When people with prejudices are worried and feel that they have no control over a scary threat like pandemic, they will turn to the tried and true tactic of scapegoating the usual suspects: religious minorities and other persecuted communities,” says Michael Kugelman, deputy director of the Asia program at the Wilson Centre, a US based think tank.

The cases of religious suppression have been on the rise around the world as a coronavirus epidemic is deteriorating. BMJ, one of the top four medical journals in the world, released an interesting thesis titled “Religious discrimination is hindering the COVID-19 response“. The British Medical Journal, BMJ, was first published in 1840 and is regarded as one of the world’s leading medical journal.

About 150,000 medical professionals are involved in this journal, dealing with the recent medical issue and providing medical knowledge and information concerned. Just about 20 percent theses submitted to BMJ are published in this Journal, which are often quoted by other medical professionals around the world.

According to the research paper, India’s 201 million Muslim citizens now find themselves blamed for the country’s COVID-19 outbreak. In the southern Indian state of Karnataka, two Muslim men were reportedly beaten and made to kneel and apologize for “spreading the virus.”

Over 3000 members of the Tablighi Jamaat subsequently spent more than 40 days in quarantine with government authorities refusing to discharge them. The Indian government levelled charges of culpable homicide at Tablighi Jamaat chief Muhammad Saad Kandhalvi when at least six of the group died of the infection after attending an event in March, before the countrywide lockdown.

In Cambodia, Buddhists are blaming Muslims. In Israel, Jews are blaming Arabs. Fear and misunderstanding are stoking hatred worldwide—and it is harming the fight against the pandemic.

The paper introduces a case in South Korea, the members of the Shincheonji Church of Jesus—labelled “heretical” by fundamentalist Protestants—are facing a probe after a congregation became the center of the country’s biggest outbreak in February. But what’s striking is how discrimination played a part before the outbreak.

“Members of the church refrained from being tested to avoid discrimination,” says Willy Fautre, executive director of Human Rights Without Frontiers International. “This was detrimental to them and public health as well.”

They are extremely careful about their religion exposed to others for the fear that they can get discriminated, bullied, or unemployed because of their religion.

Actually, it is reported that about 6,000 Shincheonji church members whose religious identity was revealed to others experienced severe discrimination and unemployment, and two of them lost their lives.

Despite the tragic incidences, about 4,000 former COVID-19 patients of Shincheonji members who got cured have decided to donate their blood plasma for the development of treatments for COVID-19. The donation of the blood plasma of 500 former COVID-19 patients has started this week.

Swami Vedanand Saraswati, Spiritual Head of Arya Samaj in South Africa – “I firmly believe that the Chairman, a man of great integrity, has done and continues to do all in his power to aid in fighting against the COVID-19 virus, and assist the relevant authorities where possible. As a Hindu Spiritual Leader in South Africa, I fully support the Chairman and laud the selfless gesture from him and his congregation. I implore the South Korean Government and other relevant authorities to immediately drop all charges and lawsuits and rather support the efforts of the Shincheonji Church in encouraging other recoverees to donate their plasma. Let us all follow the noble example set by the Chairman and encourage support towards the fight against COVID-19.”

Furthermore, Dr. Manu Singh, Hindu Spiritual Leader, Chairman of Sarva Dharma Samvaad in India, expressed his thoughts on such a suppression of the religion. “With the suffer of a pandemic, we need to overcome the crisis by becoming the one rather than hating each other. Being the one with the solidarity will be much effective treated following the physical vaccine and the treatment. Furthermore, the freedom of the religion specified in the constitution should be kept. I raise the voice to stop unfair treat to HWPL and Shincheonji church, and the Chairman Lee who sacrificed part of his freedom.”

EDITOR’S NOTE: Image at https://www.newsamericasnow.com/wp-content/uploads/2020/07/religious_freedom.jpg

Click Here for More Information »

500 Recovered Congregation Members of Shincheonji Church Donate COVID-19 Blood Plasma

CaribPR Wire, VIRGINIA BEACH, Virginia, Weds. July 16, 2020: Among the members of the Shincheonji Church, 500 people from Shincheonji Church, who have recovered from COVID-19, are donating blood plasma this week.

The Korea Centers for Disease Control and Prevention, in cooperation with the Korean Red Cross, set up mobile plasma sites to extract blood plasma from 500 congregation members of Shincheonji who have recovered from COVID-19. This represents a 200% uptick in plasma donations in South Korea. Before the mass donation, South Korean officials reported that about 170 people’s blood plasma were collected nationwide.

In June, 4,000 members of Shincheonji pledged to donate blood plasma. Due to logistical issues, 55 members were able to donate blood plasma before this week. The 500 members’ blood plasma will be procured within the week by using blood donation cars that can extract blood in large quantities. This is thought to be the first round of donations.

Health officials from the Mayo Clinic and U.S. Food and Drug Administration believe that plasma donations may contribute greatly to the treatment of COVID-19 patients as well as contribute to the research and development of novel immunotherapies. Preliminary results of one trial cited by UpToDate, showed a statistically significant rate of improvement in patients treated with donated plasma compared to those who received standard therapies (91% compared to 68% respectively).

The plasma donated by Shincheonji will be used to make similar treatments after clinical trials.

EDITOR’S NOTE:  Images at:

https://www.newsamericasnow.com/wp-content/uploads/2020/07/1.jpeg

https://www.newsamericasnow.com/wp-content/uploads/2020/07/2.jpg

Click Here for More Information »

Man-Hee Lee Writes A Letter Regarding Shincheonji Members’ Plasma Donation: “Freeing The World Through Our Blood”

CaribPR Wire, VIRGINIA BEACH, VA, Tues. June 30, 2020: Man Hee Lee, Chairman and Founder of Shincheonji Church of Jesus, the Temple of the Tabernacle of the Testimony (Shincheonji), has  expressed his gratitude to his church members and the city of Daegu, after 4,000 congregants volunteered to donate plasma after fully recovering from COVID-19.

According to the Shincheonji church in the city of Daegu, Chairman Lee in a  letter stated: “I was overjoyed to hear that the church members in Daegu, South Korea were volunteering to donate plasma (blood) to help find a treatment for COVID-19.  I am thankful to the government for working to prevent the spread of COVID-19 and to treat those who are infected.” He added, “it is clear that the church members of Daegu church have gathered their hearts to free people worldwide from the pains of COVID 19.”

Chairman Lee also stated through this message” “This is the work that needs to be done as citizens of this country [Korea] and as true believers. It is keeping the command of Jesus of loving your neighbor as yourself (Mt 22:39), and I am thankful that you have gathered your hearts for this good work”.. “let us all pray in the name of Jesus to exterminate COVID19 (Refer to Jn14:13-14).”

Shincheonji announced it’s donation on June 23rd. At the time, there were 6,901 confirmed COVID-19 cases in Daegu, South Korea, with Shincheonji members accounting for 61.8% of all confirmed cases of COVID-19.

While it has been difficult to find plasma donors, Shincheonji members’ mass plasma donation can speed up the COVID-19 vaccine development process. Since the early days of the outbreak Shincheonji members have faced mass criticism. Many outlets blame them for causing the virus’s spread across South Korea.

Shincheonji explained, “Chairman Lee wants to use this donation as a way to thank government health officials for caring for our members.”

Shincheonji Chairman Lee Man-hee’s Letter [Provided by Shincheonji Church in Daegu]

To the beloved members of Daegu Church

To the beloved members of Daegu Church, you all are working hard. Are you all well? I am Chairman Lee Man-hee.

To the members of Daegu church, I was delighted upon hearing the news of your intent to actively participate in donating plasma (blood) for the development of the vaccine for the cure of COVID-19. I believe that you are the ones who received the blood of Jesus.

I am very thankful to the government, which took charge of preventing the spread of COVID-19 and providing treatment for it. This is not something our church could resolve.

Our members have received the blood of life of Jesus, the Son of God, and have been freed from sin. Like Jesus, through our blood (plasma) donation, I know that you have gathered your hearts in our collective wish to free all the people of the world from the pains of this disease.

I was touched when I heard that many members of Daegu church expressed their intent to voluntarily donate plasma. Indeed, you are the disciples who received the blood of Jesus. This is the work that needs to be done as citizens of this country and as true believers. It is keeping the command of Jesus of loving your neighbor as yourself (Mt 22:39), and I am thankful that you have gathered your hearts for this good work and in making this decision that is like the light.

Let us all pray in the name of Jesus to exterminate COVID-19 (Refer to Jn14:13-14).

June 27, 2020

Lee Man-hee
Chairman of Shincheonji

Click Here for More Information »

Correction in Total COVID-19 Deaths for Latin American and Caribbean Nations

SEATTLE, June 25, 2020 /PRNewswire-HISPANIC PR WIRE/ – An unintentional error in calculating total deaths for Latin America and the Caribbean resulted in IHME issuing an incorrect total for the region in a June 24 press release and on its website. The reported total of nearly 388,300 excluded Argentina, Chile and Uruguay. The updated total for Latin America and the Caribbean is 438,698 deaths. IHME regrets the error.

The forecasted deaths for individual nations are correct. IHME will continue to update as new data are available.

The forecasts can be viewed at https://covid19.healthdata.org.

Logo - https://mma.prnewswire.com/media/1156878/IHME_Logo.jpg

Click Here for More Information »

New IHME COVID-19 Model Forecasts Latin American, Caribbean Nations Will See Nearly 388,300 Deaths by October 1

SEATTLE, June 24, 2020 /PRNewswire-HISPANIC PR WIRE/ – The Institute for Health Metrics and Evaluation (IHME) at the University of Washington is forecasting nearly 388,300 people will die from COVID-19 in Latin American and Caribbean nations by October 1.

Brazil is expected to exceed 166,000 deaths and Mexico 88,000. Six other nations are each predicted to exceed 10,000: Argentina, Chile, Colombia, Ecuador, Guatemala, and Peru. In contrast, 15 nations, including Paraguay, Uruguay, and Belize are each expected to have fewer than 1,000 deaths.

“Several Latin American countries are facing explosive trajectories, while others are containing infections effectively,” said IHME Director Dr. Christopher Murray. “I cannot overemphasize the imperative of mitigation measures, such as mask wearing and social distancing, especially since South American nations are facing increasing infections due to seasonality of COVID-19, an important factor contributing to the transmission of the virus.”

IHME’s new forecasts model deaths from the virus if countries impose social distancing mandates for six weeks at the point when deaths reach 8 per million people, comparing that to a scenario if no action is taken. The percentage of people wearing masks when leaving their home is also a key consideration.

“These factors are vital in our projections and highlight how many lives can be saved,” Murray said.

He noted that the number of deaths is certain to continue to rise in nations where mandates on mask wearing and social distancing are relaxed. In contrast, Murray stated transmission might be reduced by as much as 50% in communities where individuals are wearing masks when leaving their homes, either voluntarily or by mandate.

The forecasts by nation:

Southern, Tropical, and Andean Latin America

  • Argentina: 24,721 deaths (range of 9,386 to 61,163)
  • Chile: 25,344 deaths (range of 18,094 to 34,509)
  • Uruguay: 340 deaths (range of 52 to 2,075)
  • Bolivia: 7,334 deaths (range of 3,564 to 13,645)
  • Ecuador: 20,260 deaths (range of 16,069 to 27,103)
  • Peru: 36,210 deaths (range of 28,145 to 48,617)
  • Brazil: 166,362 deaths (range of 135,538 to 208,079)
  • Paraguay: 271 deaths (range of 27 to 1,952)

Central America and Mexico

  • Colombia: 35,314 deaths (range of 14,640 to 81,942)
  • Costa Rica: 39 deaths (range of 17 to 120)
  • El Salvador: 4,357 deaths (range of 668 to 15,546)
  • Guatemala: 10,090 deaths (range of 3,874 to 22,071)
  • Honduras: 4,958 deaths (range of 881 to 14,207)
  • Mexico: 88,160 deaths (range of 67,967 to 120,023)
  • Nicaragua: 280 deaths (range of 72 to 2,276)
  • Panama: 2,802 deaths (range of 1,315 to 5,895)
  • Venezuela: 2,893 deaths (range of 84 to 29,295)

The Caribbean

  • Antigua and Barbuda: 10 deaths (range of 2 to 74)
  • Bahamas: 26 deaths (range of 10 to 121)
  • Barbados: 46 deaths (range of 8 to 282)
  • Belize: 20 deaths (range of 3 to 143)
  • Cuba: 306 deaths (range of 180 to 663)
  • Dominican Republic: 5,665 deaths (range of 1,731 to 15,650)
  • Guyana: 14 deaths (range of 12 to 24)
  • Haiti: 1,377 deaths (range of 202 to 5,919)
  • Jamaica: 68 deaths (range of 17 to 364)
  • Suriname: 698 deaths (range of 28 to 2,541)
  • Trinidad and Tobago: 440 deaths (range of 13 to 6,868)
  • Puerto Rico: 286 deaths (range of 185 to 605)
  • United States Virgin Islands: 7 deaths (range of 6 to 11)

The new death projections and other information, such as hospital resources usage, are available at https://covid19.healthdata.org.

Contact: media@healthdata.org

A note of thanks

We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimation efforts possible: ACAPS; American Hospital Association; Bill & Melinda Gates Foundation; Blavatnik School of Government, University of Oxford; Bloomberg Philanthropies; Boston Children’s/Health Map; California Health Care Foundation; Carnegie Mellon University; Christopher Adolph and colleagues at the Department of Political Science, University of Washington; Descartes Labs; Facebook Data for Good; Google Labs; John Stanton & Theresa Gillespie; Julie & Erik Nordstrom; Kaiser Family Foundation; Medtronic Foundation; Microsoft AI for Health; National Institute on Minority Health and Health Disparities (NIMHD) at the National Institutes of Health (NIH); National Science Foundation; Our World in Data; Premise; Qumulo; Real Time Medical Systems; Redapt; SafeGraph; The COVID Tracking Project; The Johns Hopkins University; The Kuwait Foundation for the Advancement of Sciences (KFAS); The New York Times; UNESCO; University of Maryland; University of Miami Institute for Advanced Study of the Americas (Felicia Knaul and Michael Touchton); Wellcome Trust; World Health Organization; and finally, the many Ministries of Health and Public Health Departments across the world, collaborators and partners for their tireless data collection efforts. Thank you.

About the Institute for Health Metrics and Evaluation

The Institute for Health Metrics and Evaluation (IHME) is an independent global health research organization at the University of Washington School of Medicine that provides rigorous and comparable measurement of the world’s most important health problems and evaluates the strategies used to address them. IHME is committed to transparency and makes this information widely available so that policymakers have the evidence they need to make informed decisions on allocating resources to improve population health.

Logo - https://mma.prnewswire.com/media/1156878/IHME_Logo.jpg

Click Here for More Information »

Baptist Health Unveils New Safety Measures as Elective Surgeries and Procedures Resume

New Steps Geared Towards Protecting Patients and Employees

MIAMI, May 20, 2020 /PRNewswire-HISPANIC PR WIRE/ — Baptist Health South Florida has announced new comprehensive safety guidelines as it welcomes back more patients and ramps up operations to fully restore in-person health services system wide. As Baptist Health resumes elective surgeries and procedures, enhanced safety precautions have been introduced to prevent the spread of infection and to ensure every facility including emergency rooms, urgent care centers and physician offices can safely care for patients who need healthcare.

In an effort to promote safety, cleanliness and social distancing, here are some of the changes patients, employees and visitors can now expect at Baptist Health facilities:

  • Enhanced Cleaning of High-touch Areas
  • Universal Mask Use
  • Contactless Registration
  • Point-Of-Entry Screening
  • Wait Where You Feel Comfortable, including in some cases, in your car
  • Hand-sanitizing Stations
  • Touch-free sliding doors
  • COVID-19 Patients Treated in Separate Area
  • Front Desk Plexiglass partitions
  • Social Distance Floor Markings
  • Chairs Spaced Out
  • Magazines Removed from Tables
  • Coffee and Snack Service Suspended

“As one of the leading healthcare providers in the region, our patients and employees have come to expect the highest standards in health and safety from us,” said Bo Boulenger, Executive Vice President and Chief Operating Officer at Baptist Health South Florida. “Now more than ever, our patients rely on our care and we are ready to care for them, especially those who may have delayed treatment during the pandemic. Through these steps, we are confident we can protect our patients and employees as we safely care for our community.”

These safety measures are based on information from the Centers for Disease Control and Prevention, the World Health Organization, the American Hospital Association, the Florida Governor’s Office and the White House’s Opening Up America Again guidelines.

For more information on Baptist Health’s safety plan, visit our Patient and Visitor Safety page at https://baptisthealth-coronavirus.com/patients-and-visitors.

About Baptist Health South Florida

Baptist Health South Florida is the largest healthcare organization in the region, with 11 hospitals, more than 23,000 employees, 4,000 physicians and 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on FacebookInstagramTwitter and LinkedIn.

Photo - https://mma.prnewswire.com/media/1170894/Baptist_Health_Because_We_Care_Safety_First_INFOGRAPHIC.jpg

Click Here for More Information »

Prominent neurosurgeon Michael McDermott, M.D., joins Baptist Health South Florida to lead Miami Neuroscience Institute

CORAL GABLES, Florida, April 30, 2020 /PRNewswire-HISPANIC PR WIRE/ — Baptist Health South Florida welcomes Michael McDermott, M.D., a world-renowned leader in neurosciences with clinical expertise in the field of meningioma research and gamma knife radiosurgery, as its new chief medical executive of Miami Neuroscience Institute, formerly known as Baptist Health Neuroscience Center.

Dr. McDermott, widely known for advancing neurosurgical techniques, pioneered surgical management of meningioma, a slow-growing tumor in the head that affects the brain. He is an expert in the treatment of a wide variety of neurological disorders, in addition to meningiomas, skull base tumors, brain metastases, gliomas, hydrocephalus, central nervous system infections and complex tumors of the skull base and spinal cord.

“I am delighted to have a colleague of his caliber join our organization,” said Michael Zinner, M.D., chief executive officer and executive medical director at Miami Cancer Institute, part of Baptist Health South Florida. “His expertise will help enhance our collaborative and interdisciplinary approach to research and delivery of the best cancer treatments for our patients.”

Dr. McDermott has conducted leading research that generated more than 400 peer-reviewed publications and comes from the University of California San Francisco (UCSF) Medical Center, ranked by U.S. News & World Report as third in the nation in neurology and neurosurgery, where he was co-director of the Gamma Knife and CyberKnife Radiosurgery Program and held the distinguished Wolfe Family Endowed Professorship in Meningioma Research. In addition to serving as professor and vice chairman of neurological surgery, he is an accomplished educator. As residency program director, he trained young physicians from around the world.

“The arrival of Dr. McDermott to lead Miami Neuroscience Institute represents Baptist Health’s ability to harness the collective expertise of physician leaders and to offer the most innovative, comprehensive and individualized care available to our patients,” said Jack Ziffer, PhD, M.D., executive vice president, chief clinical officer and chief physician executive for Baptist Health South Florida.

Miami Neuroscience Institute provides care at all the Baptist Health facilities, with the exception of Boca Raton Regional Hospital, home to the renowned Marcus Neuroscience Institute, and Bethesda Hospital East and Bethesda Hospital West’s neuroscience programs. For the first several months, Dr. McDermott will focus on working with clinical and administrative leadership to plan and build the infrastructure as well as clinical depth and breadth of the program and set the stage for growth as a destination for neuroscience care.

“The multidisciplinary team approach we have at Baptist Health creates a special synergy between medical specialists from various fields to provide the most advanced care to our patients. This exceptional physician and surgeon will complement the tremendous medical talent that resides within Baptist Health and will continue to grow our national leadership in the treatment of conditions of the brain, spine and nervous system,” added Dr. Ziffer, PhD, M.D.

Miami Neuroscience Institute

Miami Neuroscience Institute, formerly known as Baptist Health Neuroscience Center, offers comprehensive and compassionate treatment for neurological conditions affecting the brain, spinal cord and peripheral nervous system. From non-surgical treatments and minimally invasive procedures to complex brain and spine surgery, the Center embraces a multidisciplinary approach to patient care.

Miami Neuroscience Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with 11 hospitals, nearly 23,000 employees, more than 4,000 physicians and more than 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on FacebookInstagramTwitter and LinkedIn.

Click Here for More Information »

Baptist Health International Cayman Islands PET & CT Imaging Center Receives Prestigious Recognition for Superior Patient Care

The Imaging Center was awarded the Gold Seal of Approval from the Joint Commission International (JCI), the first for Baptist Health South Florida outside the U.S.

The accreditation recognizes the Center for its high quality and standards in patient care.

GEORGE TOWN, Cayman Islands, March 12, 2020 /PRNewswire-HISPANIC PR WIRE/ – Baptist Health International Cayman Islands PET & CT Imaging Center, part of Baptist Health South Florida, was awarded the Gold Seal of Approval from the Joint Commission International (JCI), a global leader in accrediting quality in healthcare. This is the first JCI accreditation for Baptist Health South Florida outside the U.S. and positions the Imaging Center as one of the prestigious facilities around the world that are dedicated to achieving the highest standards in quality and safety in patient care.

“This recognition is a testament to our long-standing commitment to providing our patients in the Cayman Islands and the Caribbean with superior care when it comes to their health,” said Rogelio E. Ribas, corporate vice president of Baptist Health International. “We look forward to continuing the enhancement of our services and technology so that patients can have access to quality diagnostic imaging services and transforming the Cayman Islands into a top medical destination in the region.”

Accreditation was awarded following a detailed and comprehensive on-site survey and evaluation process, ensuring that the Imaging Center met the criteria in every area. JCI’s stringent standards – addressing topics such as patient education, qualification and competency of staff, the use of data to improve services and preparedness for emergencies – are updated regularly to reflect the advances in healthcare.

Baptist Health International Cayman Islands PET & CT Imaging Center is equipped with state-of-the-art positron emission tomography (PET) and computed tomography (CT) technology. It provides the latest solutions in diagnostic imaging, servicing patients not only in the Cayman Islands, but also those in other Caribbean countries who may not have access to these advanced technologies in their counties. Since its opening in 2019, the Imaging Center has provided more than 400 patients with diagnostic consults, reducing the need to travel abroad for a PET or CT scan.

About Baptist Health International
Baptist Health International is one of the largest hospital-based international programs in the United States, with more than 12,000 international patient visits at Baptist Health South Florida facilities from the Florida Keys to Palm Beach County. Baptist Health International is dedicated to providing comprehensive, high-quality services for international physicians and their patients, including hospital admissions, outpatient medical exams, medical second opinions and physician consultations, as well as concierge services.

About Baptist Health South Florida
Baptist Health South Florida is the largest healthcare organization in the region, with 11 hospitals, more than 23,000 employees, 4,000 physicians and 100 outpatient centers, urgent care facilities and physician practices spanning Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune magazine as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on FacebookInstagramTwitter and LinkedIn.

Click Here for More Information »

Miami Cardiac & Vascular Institute Names Joseph T. McGinn, Jr., M.D., chief of Cardiac Surgery

MIAMI, March 4, 2020 /PRNewswire-HISPANIC PR WIRE/ — Miami Cardiac & Vascular Institute, part of Baptist Health and the region’s largest and most comprehensive cardiovascular facility, has named Joseph T. McGinn, Jr., M.D., chief of Cardiac Surgery. Dr. McGinn specializes in the assessment and surgical treatment of patients with coronary artery, aortic and vascular disease.  A pioneer in the field of cardiothoracic surgery, he developed the minimally invasive coronary artery bypass grafting method known internationally as the “McGinn Technique.”

Dr. McGinn comes to Miami Cardiac & Vascular Institute from Sanger Heart & Vascular Institute, part of Atrium HealthCare in Charlotte, North Carolina, where he served as endowed chair of Cardiovascular and Thoracic Surgery and professor of Cardiovascular and Thoracic Surgery. Prior to that appointment, he was a leading cardiac surgeon in New York City and served as medical director of the Heart Institute at Staten Island University Hospital for 16 years.

“Dr. McGinn is an expert physician and surgeon and an exceptional leader who has demonstrated excellence in patient care, innovation and team building,” said Barry T. Katzen, M.D., founder and chief medical executive of Miami Cardiac & Vascular Institute. “He will complement our team of highly skilled experts, who are committed to achieving the same goals.”

Jack A. Ziffer, Ph.D., M.D., executive vice president and chief clinical officer of Baptist Health South Florida, added, “We are pleased to have Dr. McGinn join Miami Cardiac & Vascular Institute in this leadership capacity to continue his groundbreaking work and further advance the Institute’s worldwide leadership position in the delivery of cardiovascular care.”

An accomplished educator, Dr. McGinn has trained hundreds of surgeons from around the world in minimally invasive cardiothoracic surgical techniques. His clinical and research efforts have generated hundreds of presentations at scientific symposiums and publications in peer-reviewed medical journals and books. He has been recognized by the American Heart Association for excellence in medicine and received the Samuel L. Koontz Award for Clinical Excellence. He is a Fellow of the American College of Cardiology, the American College of Chest Physicians and the American College of Surgeons and a member of numerous professional societies.

Dr. McGinn earned his medical degree at the State University of New York (SUNY) Downstate Medical Center College of Medicine. He completed an internship and residency in general surgery at SUNY Downstate, serving as chief resident. He also served as chief resident during a cardiothoracic surgery residency at Long Island Jewish Medical Center. He is board certified by the American Board of Surgery, American Board of Thoracic Surgery and the American Board of Surgery, Surgical Critical Care.

Dr. McGinn enjoys boating with his family and is an avid football fan. He has performed 1,500 MICS CABG cases.

About Miami Cardiac & Vascular Institute
Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region. The team of multilingual, multidisciplinary specialists pioneered the development of minimally invasive techniques used to treat aneurysms, blockages in veins and arteries and holes in the heart. The Institute leverages the power of Baptist Health’s combined resources of experts, pioneering research, compassionate caregivers and leading-edge treatments and technology.

Miami Cardiac & Vascular Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with 11 hospitals, more than 23,000 employees, 4,000 physicians and 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on FacebookInstagramTwitter and LinkedIn.

Photo - https://mma.prnewswire.com/media/1099414/McGinn_headshot.jpg

Click Here for More Information »

Expression Of Support For The Bahamian Community

MIAMI, Sept. 6, 2019 /PRNewswire-HISPANIC PR WIRE/ – In light of the devastating impact of Hurricane Dorian on the Bahamas, Baptist Health South Florida would like to share its deepest sympathy for the Bahamian people.

Baptist Health is taking immediate action to provide support as aid efforts begin. Rose Rahming, Baptist Health’s local representative in the Bahamas, is assisting with the coordination of relief efforts from the National Emergency Operations Centre as well as the Baptist Health International office in Nassau.

Baptist Health South Florida is working with the Bahamian authorities to provide a significant amount of medical supplies to the functioning hospital in the region, Princess Margaret Hospital located in Nassau. Baptist Health has also notified Bahamian authorities that we are prepared to support patient transfers for those affected by the storm.

Locally, we have partnered with South Florida-based Operation Helping Hands, which has been activated by United Way of Miami-Dade, to provide disaster relief to our Bahamian neighbors and friends in this critical time of need.

In the aftermath of a hurricane of this magnitude, financial contributions are critical to providing the most effective help to address the immediate needs of the affected areas. Operation Helping Hands ensures that the funds are used by organizations with the experience and infrastructure to deliver the immediate assistance needed. One hundred percent of the funds raised through Operation Helping Hands will go directly to those affected by Hurricane Dorian in the Bahamas.

For over two decades, Baptist Health has cultivated close friendships with our neighbors in the Bahamas. Although the road to recovery will be long, we stand ready and committed to assist the Bahamian people in the days, weeks, and months ahead.

About Baptist Health South Florida
Baptist Health South Florida is the largest healthcare organization in the region, with 11 hospitals, nearly 23,000 employees, more than 4,000 physicians and more than 100 outpatient centers, urgent care facilities and physician practices spanning Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to our faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on FacebookInstagramTwitter and LinkedIn.

About Baptist Health International
Baptist Health International is one of the largest hospital-based international programs in the United States. Thousands of people travel to Miami each year from around the world to receive care from the renowned physicians at Baptist Health South Florida facilities. Baptist Health International is dedicated to facilitating comprehensive, high-quality services for international physicians and their patients, including hospital admissions, outpatient services and medical exams, second opinions, physician consultations and concierge services. For more information, visit BaptistHealth.net/International.

Click Here for More Information »

If you paid for Solodyn®, a class action lawsuit may affect your rights

NEW YORK, Dec. 13, 2017 /PRNewswire-HISPANIC PR WIRE/ – You may be affected by a class action lawsuit against Medicis Pharmaceutical Corp., and Impax Laboratories, (”Defendants”). The lawsuit claims that Defendants unlawfully delayed the availability of allegedly less-expensive generic versions of Solodyn and that Defendants’ conduct caused certain consumers and third-party payors (discussed below) to pay too much for Solodyn in these states and territories. Defendants deny any wrongdoing.

ARE YOU AFFECTED?

As a consumer, you may be a member of the End-Payor Class if after July 23, 2009 you purchased or paid for some or all of the purchase price for 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg Solodyn and/or its generic versions of one or more of these dosages, in the United States and its territories, including Puerto Rico, in tablet form, for consumption by yourself or your family. Purchases made directly from Defendants, for resale purposes, for fixed dollar co-payments that do not vary between brand and generic drug, through Medicaid, or consumers who purchased Solodyn prior to July 23, 2009 are not included.

YOUR RIGHTS AND OPTIONS

DO NOTHING : If you do nothing you are choosing to stay in the End-Payor Class and you will be able to share in any money or benefits that may occur in this case. You will be bound by all orders and judgments of the Court and you will give up your right to sue the Defendants as part of any other lawsuit for the claim made in this case.

EXCLUDE YOURSELF FROM THE END-PAYOR CLASS : If you exclude yourself from the End-Payor Class (i.e. opt out), you will not be entitled to money or benefits if they are awarded or obtained. You will be bound by all orders and judgments of the Court and you will give up your right to sue the Defendants as part of any other lawsuit for the claim made in this case. The deadline to exclude yourself from the End-Payor Class is February 10, 2018.

THE TRIAL

The Court will hold a trial in this case on March 12, 2018 at the United States District Court for the District of Massachusetts, 1 Courthouse Way Boston, Massachusetts 02210. You may hire your own lawyer at your own expense, but you do not have to.

WANT MORE INFORMATION?

Go to www.SolodynCase.com, call 1-800-332-7414, or write to In re Solodyn Antitrust Litigation (End-Payor Action), P.O. Box 173034, Milwaukee, WI 53217.

800-332-7414
www.SolodynCase.com

Click Here for More Information »

Henry Schein Disaster Relief Hotline Remains Open To Support Customers Affected By Hurricane Maria

Dentists, Physicians, and Veterinarians Who May Experience Operational, Logistical, or Financial Issues Encouraged to Call 800-999-9729

MELVILLE, N.Y., Sept. 20, 2017 /PRNewswire-HISPANIC PR WIRE/ – Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers in Puerto Rico, the Caribbean, and all areas in the projected path of Hurricane Maria, that the Henry Schein Disaster Relief Hotline is open for dentists, physicians, and veterinarians who may experience operational, logistical, or financial issues as a result of damage caused by the storm.

The toll-free number for all Henry Schein customers is 800-999-9729. The hotline is open 24/7, with real-time assistance available from Team Schein Members from 8 a.m. to 7 p.m. ET.  The Henry Schein Disaster Relief Hotline remains open throughout the year to provide assistance to practitioners during their preparation and recovery from disasters.

To help meet the challenges of rebuilding a practice in the wake of a natural disaster, practitioners can download our Recovery Guide for Office-Based Practitioners and visit our Road to Recovery Resource Center for more resources and information.

“Our thoughts and prayers are with the people and communities of Puerto Rico, the Caribbean, and all areas preparing for Hurricane Maria’s potential impact,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “We encourage health care providers whose practices may sustain damage during the storm to contact our disaster relief hotline and visit our web-based Road to Recovery Resource Center for assistance in reopening their practices as soon as possible.”

About Henry Schein Cares
Henry Schein Cares stands on four pillars: engaging Team Schein Members to reach their potential, ensuring accountability by extending ethical business practices to all levels within Henry Schein, promoting environmental sustainability, and expanding access to health care for underserved and at-risk communities around the world. Health care activities supported by Henry Schein Cares focus on three main areas: advancing wellness, building capacity in the delivery of health care services, and assisting in emergency preparedness and relief.

Firmly rooted in a deep commitment to social responsibility and the concept of enlightened self-interest championed by Benjamin Franklin, the philosophy behind Henry Schein Cares is a vision of “doing well by doing good.” Through the work of Henry Schein Cares to enhance access to care for those in need, the Company believes that it is furthering its long-term success. “Helping Health Happen Blog” is a platform for health care professionals to share their volunteer experiences delivering assistance to those in need globally. To read more about how Henry Schein Cares is making a difference, please visit our blog: www.helpinghealthhappen.org.

About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is the world’s largest provider of health care products and services to office-based dental, animal health and medical practitioners. The company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and the Nasdaq 100® indexes, Henry Schein employs more than 21,000 Team Schein Members and serves more than 1 million customers.

The company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. The company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 32 countries. The company’s sales reached a record $11.6 billion in 2016, and have grown at a compound annual rate of approximately 15 percent since Henry Schein became a public company in 1995. For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein and @HenrySchein on Twitter.

Click Here for More Information »

Oxitec’s Friendly™ Aedes Mosquito Receives Positive Evaluation for European Standard in relation to Human Health and the Environment

RIVM concludes negligible risk of Oxitec’s Friendly™ Aedes mosquitoes

France’s High Council for Biotechnology also publishes Supportive Position

OXFORD, England, July 12, 2017 /PRNewswire-HISPANIC PR WIRE/ –The National Institute of Public Health and the Environment (RIVM) in the Netherlands today published its “Technical evaluation of a potential release of OX513A Aedes aegypti mosquitoes on the island of Saba“, which positively concludes a vector control program using Oxitec’s Friendly™ Aedes aegypti mosquitoes would pose negligible risks to human health and the environment.

(Logo: http://photos.prnewswire.com/prnh/20150630/227348 )

RIVM’s GMO office undertook its biosafety evaluation of Oxitec’s Friendly™ self-limiting mosquito technology following the guidance for risk assessment of genetically modified animals by the European Food Safety Authority (EFSA) and the European risk assessment framework, which is considered one of the most robust and thorough biosafety frameworks globally.  Additionally this independent review reflected guidance from the World Health Organization (WHO) for testing of genetically modified mosquitoes as well as the Cartagena Protocol on the Biosafety to the Convention on Biological Diversity.

“We welcome the favorable outcome of the RIVM’s extensive review indicating a positive safety profile of our bio-based mosquito technology,” said Mark Carnegie-Brown Chief Executive Officer at Oxitec. “When combined with our excellent efficacy data, this result points to the significant potential of the Oxitec platform to safely address the growing global challenge from dangerous Aedes aegypti mosquitoes. We are committed to working with regulators worldwide to bring this important technology to market.”

This result reinforces the affirmative biosafety profile of Oxitec’s self-limiting technology for deployment in vector control programs, and also supports the conclusions of environmental assessments conducted elsewhere including from Brazil’s National Technical Commission of Biosafety (CTNBio) and the U.S. Food and Drug Administration (FDA) whose review team consisted of experts from the Center for Veterinary Medicine, the Centers for Disease Control and Prevention, and the Environmental Protection Agency.

Additionally, France’s High Council for Biotechnology (HCB) last month published its supportive position on the use of genetically modified mosquitoes for vector control, following the emergence of mosquito-borne diseases in French overseas territories and perceived threats to metropolitan France. Oxitec has been working closely with the HCB to help inform their evaluation and welcomes HCB’s opinion on self-limiting Aedes aegypti. The HCB opinion will help to shape the policy landscape in France towards the deployment of new tools for vector control, and is a positive step towards advancing Oxitec vector control projects in the French Caribbean.

How Friendly™ Aedes works

Oxitec has been working in Aedes aegypti control for over a decade and pioneered the use of a biological method to suppress wild populations of this dangerous mosquito species through the release of Friendly™ Aedes males, which do not bite and do not transmit diseases. When released, these males search for wild females to mate, and their offspring inherit a self-limiting gene that causes them to die before reaching functional adulthood.  Friendly™ Aedes’ offspring also inherit a fluorescent marker that allows tracking and monitoring at a level never before achieved, making the assessment of effectiveness more accurate throughout the whole Friendly™ Aedes deployment program. Unlike other approaches, Friendly™ Aedes mosquitoes die along with their offspring, and therefore do not persist in the environment or leave any ecological footprint.

About Oxitec

Oxitec is a pioneer in using genetic engineering to control insect pests that spread disease and damage crops, and was founded in 2002 as a spinout from Oxford University (UK). Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world’s biggest problems.  Follow us on Twitter at @Oxitec.

Click Here for More Information »

Partial Settlement of a Class Action Lawsuit for Purchasers of Solodyn and/or Its Generic Equivalent is Announced

NEW YORK, April 28, 2017 /PRNewswire-HISPANIC PR WIRE/ –

If You Purchased Solodyn and/or Its Generic Equivalent Partial Settlements of a Class Action Lawsuit May Affect Your Rights

Partial settlements have been reached in a class action lawsuit involving the antibiotic drug Solodyn. The lawsuit claims that Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. (the “Defendants”) violated state competition (i.e. antitrust and consumer protection) and unjust enrichment laws by agreeing not to compete with each other and keeping lower-cost generic versions of Solodyn off the market. The Defendants deny this. No one is claiming that Solodyn is unsafe or ineffective.

WHAT DO THE SETTLEMENTS PROVIDE?

To settle the lawsuit, Lupin Pharmaceuticals Inc. and Lupin Limited (”Lupin Defendants”) and Sandoz Inc. (”Sandoz”) have each agreed: (a) that they would be willing to provide certain witnesses that Plaintiffs could call and a declaration that the Plaintiffs could use during the Solodyn case involving the overall End-Payor Class, other Plaintiffs, and the Non-Settling Defendants; and (b) to deposit $625,000 and $1.75 million, respectively, into Settlement Funds. If the Settlements are approved by the Court and become final, the Settlement Funds, inclusive of interest, will be used to: (1) pay for costs and expenses incurred or to be incurred by Counsel in continuing the lawsuit against Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., and Impax Laboratories, Inc. (the “Non-Settling Defendants”); (2) cover taxable costs and taxes payable on the Settlement Funds; (3) pay for notice and other expenses; and (4) pay for service awards not to exceed $10,000 to the class representatives in recognition of their efforts to date on behalf of the Classes. Any remainder in the Settlement Funds, after the payment of the above expenses, shall be distributed to the End-Payor Class for the Lupin Settlement and the End-Payor Class for the Sandoz Settlement in a manner approved by the Court at the conclusion of the litigation. The Settlement Agreements, available at the website www.SolodynCase.com contain more details. These Settlements involve only the Lupin Defendants and Sandoz. The case will continue against the Non-Settling Defendants.

WHO IS INCLUDED IN THE CLASSES?

Generally, you are included in the Classes if you purchased, paid and/or provided reimbursement for some or all of a Solodyn and/or its generic equivalent prescription in the United States and its territories, including Puerto Rico, in tablet form, from July 23, 2009, onward. Certain third-party payors are also members of the Classes.

You are NOT a member of the Classes if: you paid a “flat co-payment” for all of your prescription drug purchases regardless of whether they are brand or generic; you are one of the Defendants or an officer, director, manager, employee, subsidiary, or affiliate of any Defendant(s); you purchased only directly from Defendants or for resale purposes; you purchased or received Solodyn or its generic equivalent only through a Medicaid program; you are the judge in this lawsuit or a member of the judge’s immediate family; and/or you previously excluded yourself from the overall End-Payor Class.

YOUR RIGHTS AND OPTIONS

If you are a Class Member, you have the right to exclude yourself (to opt-out) from one or both of the Settlements no later than June 12, 2017. You may also comment on or object to one or both of the proposed Settlements. To do so, you must act by June 12, 2017. Details on how to request exclusion, comment, or object are at www.SolodynCase.com.

The Court will hold a hearing tentatively set for 3:00 p.m. on November 27, 2017, to consider whether the Settlements and all of their terms are fair, reasonable, and adequate. Please check the website for updates.

FOR MORE INFORMATION
Visit www.SolodynCase.com
Call 1-800-332-7414

Click Here for More Information »

Oxitec Opens Large Scale Mosquito Production Facility in Brazil

Capacity to Produce 60 Million Friendly™ Aedes per Week can Help Protect Up to 3 Million Brazilians from Primary Vector for Zika, Dengue and other Viruses

OXFORD, England, Oct. 26, 2016 /PRNewswire-HISPANIC PR WIRE/ –Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its wholly owned subsidiary Oxitec has opened its new Friendly™ Aedes mosquito production facility in Piracicaba, Brazil.  The new 5,000 m² facility has the capacity to produce 60 million Friendly™ Aedes per week which can help protect up to 3 million people by significantly reducing local populations of the dangerous Aedes aegypti mosquito.

Intrexon Corporation logo.

Lieutenant General (Ret.) Thomas P. Bostick, Ph.D., P.E., Senior Vice President and Head of Intrexon’s Environment Sector stated, “The scalability of our biological solution has taken a meaningful step forward with the inauguration of this new world-class facility in Brazil.  With the rising global incidence of harmful viral infections including Zika, dengue, chikungunya, yellow fever, and now Mayaro, driven primarily by the bite of the dangerous Aedes aegypti, it is essential we make Oxitec’s proven, unparalleled Friendly™ Aedes vector control solution more available to the many countries this disease-spreading mosquito has invaded.  We continue to engage and work with numerous government agencies and non-governmental organizations to achieve this mission.”

Oxitec’s pioneering biological method involves the release of engineered, non-biting male mosquitoes that mate with wild females.  The resulting offspring inherit a self-limiting gene preventing them from reaching adulthood and the males themselves die within days providing an eco-friendly solution that solely targets Aedes aegypti and does not persist in the environment.  Oxitec will utilize a portion of the new facility’s significant production capability to support its ongoing deployment program in Piracicaba’s downtown area and CECAP/Eldorado district to suppress Aedes aegypti.

In conjunction with independent collaborators, Oxitec has conducted five open field trials of its self-limiting mosquitoes in Brazil, Panama and the Cayman Islands.  Each trial led to a greater than 90% reduction of the wild Aedes aegypti population, achieving these unparalleled suppression results within six months on average.  More recently, Piracicaba’s Epidemiologic Surveillance service released data showing the incidence of dengue had decreased by 91% to just 12 cases in the CECAP/Eldorado district where Friendly™ Aedes mosquitoes were released, compared to a 52% reduction in the rest of the city during the same 12-month period.

Notably the public support for the Friendly™ Aedes project has been strong. A survey conducted by the CW7 Market Research Institute in mid-2016 showed that 98% of Piracicaba’s citizens support the use of innovative tools to fight dengue, Zika and chikungunya, and 88% support the use of Friendly™ Aedes.

“This Friendly™ Aedes facility increases our current production capacity 30-fold in Brazil”, says Glen Slade, Oxitec’s VP and Director of Oxitec do Brasil. “This reaffirms our ability to produce Friendly™ Aedes at scale, and we are ready to expand our production even further to help protect the people of Brazil and beyond.”

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA to create biologically-based products that improve the quality of life and the health of the planet.  The Company’s integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells.  We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon.

Trademarks
Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

Click Here for More Information »

FDA Publishes Final Finding of No Significant Impact and Environmental Assessment on Oxitec’s Self-limiting Mosquito

OXFORD, United Kingdom, Aug. 5, 2016 /PRNewswire-HISPANIC PR WIRE/ — The US Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM) today published a final finding of no significant impact (FONSI) and final environmental assessment (EA) on Oxitec’s self-limiting OX513A Aedes aegypti mosquito for an investigational trial in the Florida Keys.  The finding concludes that a field trial of the Company’s genetically engineered (GE) OX513A mosquitoes in Key Haven, Florida, will not result in a significant impact on the environment.

The publication of the final FONSI and EA follows an FDA-led evaluation of potential impacts on health and the environment of the proposed trial. This culminated in the publication of a preliminary FONSI in March 2016, after which there was a period of public comment. These public comments were reviewed by the FDA-led team before the final documents were published today.

Oxitec’s Chief Executive Officer Hadyn Parry said, “We’ve been developing this approach for many years, and from these results we are convinced that our solution is both highly effective and has sound environmental credentials. We’re delighted with the announcement today that the FDA, after their extensive review of our dossier and thousands of public comments for a trial in the Florida Keys, have published their final view that this will not have a significant impact on the environment. We are now looking forward to working with the community in the Florida Keys moving forward.”

The purpose of the proposed trial is to determine the efficacy of Oxitec’s self-limiting mosquitoes for the control of the local population of Aedes aegypti in Key Haven, Monroe County, Florida.

Oxitec’s self-limiting mosquitoes have been genetically engineered so that their offspring die before reaching adulthood. Male Oxitec mosquitoes, which do not bite or spread disease, are released to mate with wild female Aedes aegypti so that their offspring die, reducing the population. Efficacy trials in Brazil, Panama, and the Cayman Islands have tested this approach, and in each of these trials the population of Aedes aegypti was reduced by more than 90% – an exceptional level of control compared to conventional methods, such as insecticides.

The FDA review team consisted of experts from the Center for Veterinary Medicine (CVM), the Centers for Disease Control and Prevention (CDC), and the Environmental Protection Agency (EPA). The FDA led an extensive review of evidence from trials in urban environments performed in Brazil and the Cayman Islands since 2009, and data from numerous safety studies, site inspections and independent experts.

For more information:

Oxitec Florida Keys Project FAQ: http://www.oxitec.com/health/florida-keys-project/

Florida Keys Mosquito Control District: http://keysmosquito.org/latest-gm-information/

About Oxitec

Oxitec is a pioneer in using genetic engineering to control insect pests that spread disease and damage crops, and was founded in 2002 as a spinout from Oxford University (UK). Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world’s biggest problems.

Oxitec Contact:
Matthew Warren
Press Officer
Tel: +44 (0) 1865 832 393
info@oxitec.com

Click Here for More Information »

Dengue Fever Cases Drop 91% in Neighbourhood of Piracicaba, Brazil, Where Oxitec’s Friendly™ Aedes Were Released

Epidemiological surveillance year ended in July 2016 with 12 cases reported for the disease in CECAP/Eldorado, compared to 133 in the year that preceded it

OXFORD, England, July 14, 2016 /PRNewswire/ — Piracicaba’s Epidemiologic Surveillance service released new data this week which showed a 91% reduction of dengue fever cases registered in the CECAP/Eldorado district, an area of 5,000 residents, in the 2015/2016 dengue-year as compared to the 2014/2015 period. The incidence decreased to just 12 cases in 2015/2016, the first year in which Friendly Aedes, the genetically engineered mosquitoes that fight wild Aedes aegypti, were released there, versus 133 cases in the previous year. According to Epidemiologic Surveillance the rest of the municipality saw a 52% reduction in dengue fever incidence during the same period, from 3,487 cases in the 2014/2015 period to 1,676 cases in 2015/2016.

(Logo: http://photos.prnewswire.com/prnh/20150630/227348 )

Additionally, the overall incidence rate in CECAP/Eldorado for the dengue-year 2014/2015 was 195% larger than the rate recorded for the rest of the municipality. In the dengue-year 2015/2016, the rate in CECAP/Eldorado was 45% lower than the rate in the rest of the municipality. The latest data roundup also reports zero cases of Zika and chikungunya in CECAP/Eldorado.

Area

Dengue Year**

2014/2015

2015/2016

Piracicaba*

Cases of Dengue

3,487

1,676

Population

386,449

386,449

Incidence

0.902%

0.437%

CECAP/Eldorado

Cases of Dengue

133

12

Population

5,000

5,000

Incidence

2.66%

0.24%

* Data excludes CECAP/Eldorado

** Dengue year in Brazil starts in 27th week of the calendar year and ends in 26th week of following calendar year

“Over the course of one year, we were able to bring the dengue fever incidence down by more than 50% in Piracicaba — the outcome of diligent work to eliminate still water spots, the breeding site of the mosquito,” says the city’s Secretary of Health, Pedro Mello. “In CECAP/Eldorado, where we had the Friendly Aedes project, the reduction was extraordinary, going over 90%.”

“We are delighted with the result achieved so far by Friendly Aedes which shows the potential of our approach. We hope to see this effect on a larger scale beyond the limited area of CECAP/Eldorado with our expansion into Piracicaba’s downtown city,” says Glen Slade, Oxitec do Brasil director.

Dengue-year

The dengue-year in Brazil starts in the 27th week of the calendar year and ends in the 26th week of the following year. This period is used by health surveillance services as a standard for monitoring and reporting epidemiological data of diseases transmitted by Aedes aegypti. The incidence rate for a disease in a certain area is an important element in planning the fight against the disease.

Friendly Aedes

Produced by Oxitec do Brasil, Friendly Aedes have been used in Piracicaba since April 30th 2015, when the first insects were released in CECAP/Eldorado. In January 2016, the technology had already reduced the number of wild Aedes aegyptilarvae by 82% in the treated area, compared to a non-treated area.

The success in reducing the population of wild Aedes aegypti led the City Hall to extend the project at CECAP/Eldorado for one more year. The deployment of Friendly Aedes was expanded into the city’s downtown area, comprising an area of 11 neighbourhoods and 60,000 residents. The first Friendly Aedes to be deployed in the downtown area are expected to be released in the São Judas neighbourhood by the second half of July. A contract for the expansion of the FriendlyAedes project into the downtown area was signed on May 31st. Besides São Judas, the project is intended to benefit São Dimas, Centro, Clube de Campo, Cidade Jardim, Cidade Alta, Parque da Rua do Porto, Nhô Quim, Jardim Monumento, Nova Piracicaba and Vila Rezende.

How Friendly Aedes works

Oxitec has been working in Aedes aegypti control for more than a decade. It is a pioneer in the use of a biological method to suppress wild populations of this dangerous mosquito species through the release of Friendly Aedes males, which don’t bite and don’t transmit disease. When released, these males search for wild females to mate, and their offspring inherit a self-limiting gene that makes them die before reaching functional adulthood. Friendly Aedes’ offspring also inherit a fluorescent marker that makes them easy to identify in the laboratory. This allows tracking and measuring at a level never before achieved, making effectiveness assessment and monitoring more accurate throughout the whole Friendly Aedes deployment programme.

Unlike other approaches, Friendly Aedes mosquitoes don’t leave any ecological footprint. Friendly Aedes die along with their offspring, so that their presence doesn’t linger in the environment.

About Oxitec

Oxitec is a pioneer in using genetic engineering to control insect pests that spread disease and damage crops, and was founded in 2002 as a spinout from Oxford University (UK). Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world’s biggest problems. Follow us on Twitter at @Oxitec.

Oxitec Contact:

Matthew Warren
Press Officer
+44-(0)1235-832-393
info@oxitec.com

Click Here for More Information »

Expansion of Oxitec’s Vector Control Solution in Brazil Attacking Source of Zika Virus and Dengue Fever after Positive Program Results

OXFORD, England and GERMANTOWN, Maryland, Jan. 19, 2016 /PRNewswire-HISPANIC PR WIRE/ — Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its subsidiary Oxitec and Piracicaba City Hall have expanded the ‘Friendly Aedes aegypti Project’ in Piracicaba, Brazil following strong results for controlling the Ae. aegypti mosquito population, the primary vector for dengue, chikungunya and Zika virus outbreaks around the world. In preparation of this growing program and to meet increasing demand for its proprietary vector control solution, Oxitec is initiating a new mosquito production facility in Piracicaba that will have capacity to protect over 300,000 people.

Logo – http://photos.prnewswire.com/prnh/20130919/NY83283LOGO
Logo – http://photos.prnewswire.com/prnh/20160118/323303LOGO

“We are delighted Piracicaba is encouraged by our strong results and expanding the program. Our new facility will support the roll out of our groundbreaking vector-control across the heart of the city and beyond,” said Oxitec CEO Hadyn Parry. “As the principal source for the fastest growing vector-borne infection in the world in Dengue Fever, as well as the increasingly challenging Zika virus, controlling the Aedes aegypti population provides the best defense against these serious diseases for which there are no cures.”

Following approval by Brazil’s National Biosafety Committee (CTNBio) for releases throughout the country, Piracicaba’s CECAP/Eldorado district became the world’s first municipality to partner directly with Oxitec and in April 2015 started releasing its self-limiting mosquitoes whose offspring do not survive. By the end of the calendar year, results had already indicated a reduction in wild mosquito larvae by 82%. Oxitec’s efficacy trials across Brazil, Panama and the Cayman Islands all resulted in a greater than 90% suppression of the wild Ae. aegypti mosquito population – an unprecedented level of control.

Based on the positive results achieved to date, the ‘Friendly Aedes aegypti Project’ in CECAP/Eldorado district covering 5,000 people has been extended for another year. Additionally Oxitec and Piracicaba have signed a letter of intent to expand the project to an area of 35,000-60,000 residents. This geographic region includes the city’s center and was chosen due to the large flow of people commuting between it and surrounding neighborhoods which may contribute to the spread of infestations and infections.

According to Mayor Gabriel Ferrato, “The city of Piracicaba has always sought innovative solutions to serious problems. In the case of Aedes aegypti, we looked for the tool that seemed most appropriate to help in the tough battle against this mosquito that transmits dengue, Zika and chikungunya. Based on the results presented today, we decided to extend the project in CECAP/Eldorado district for another year and also signed a record of intent to expand the project to the central area of Piracicaba. This will bring to the city a new Oxitec factory to meet demand for years to come and help protect the public’s health with this clean and innovative technology.”

Like many invasive insect species, Ae. aegypti’s territory is expanding as are the diseases it spreads, including dengue, chikungunya and Zika virus, which collectively impact over 100 countries and approximately 400 million people globally each year. Today Brazil has the highest reported incidence of dengue in the Western Hemisphere, and with both chikungunya and Zika virus having entered the country in 2014 and 2015 respectively, the Ae. aegypti mosquito has become an increasing health risk. As a result, Brazil’s Ministry of Health spent over 1.2 billion reals last year and allocated an additional 500 million reals for states and municipalities in January 2016 to combat the mosquito.

As per the recent New England Journal of Medicine publication titled “Zika Virus in the Americas — Yet Another Arbovirus Threat”, Brazil is not alone. Authors Anthony S. Fauci, M.D., and David M. Morens, M.D., from the National Institute of Allergy and Infectious Diseases noted, “The explosive pandemic of Zika virus infection occurring throughout South America, Central America, and the Caribbean and potentially threatening the United States is the most recent of four unexpected arrivals of important arthropod-borne viral diseases in the Western Hemisphere over the past 20 years.”

Samuel Broder, M.D., SVP and Head of Intrexon’s Health Sector commented, “As a vector that transmits a number of serious diseases, the Aedes aegypti mosquito poses a major threat to public health and the economic welfare of nations. Brazil has been hard hit by dengue and the situation there has been aggravated by the recent introduction of Zika virus infections leading to a startling increase in the number of children being born with microcephaly.” Dr. Broder continued, “Through the responsible engineering of biology, we demonstrate a new paradigm of species-specific vector control resulting in dramatic reductions of dangerous mosquitoes, without persistence or harm to the ecosystem, representing a major scientific, environmental and clinical advance.”

Diseases spread by the Aedes aegypti mosquito:

  • Dengue Fever infects up to 400 million people every year with an estimated 40% of the world’s population perpetually at risk.
  • Zika Virus is rapidly spreading into new countries. In 2015 it emerged in Brazil where it has been linked to a sudden increase in birth defects (microcephaly). The number of children born with microcephaly in Brazil has now risen to more than 3500.
  • Chikungunya swept into Central America and the Caribbean in 2013 with an epidemic spiking to over a million cases within only a year.
  • Yellow Fever remains a major health threat. There are an estimated 200,000 cases of yellow fever, causing 30,000 deaths, worldwide each year, with 90% occurring in Africa.

About Oxitec
Oxitec is the only GM insect company in the world and a pioneer in using genetic engineering to control insect pests that spread disease and damage crops. Oxitec was founded in 2002 as a spinout from Oxford University (UK), and is now a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world’s biggest problems. Oxitec’s self-limiting insect control targets only the one species of pest in a way that is non-toxic and pesticide-free, providing vector control that is both effective and environmentally friendly. Follow us on Twitter at @Oxitec.

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA to create biologically-based products that improve the quality of life and the health of the planet. The Company’s integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon.

Trademarks
Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:
Corporate Contact:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com

Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
investors@intrexon.com

Oxitec Contact:
Chris Creese, Ph.D.
Communications Manager
Tel: +44 (0) 7972 103372
info@oxitec.com

Media Contact:
Elana Ferrari
Edelman US
Tel: +1 (312) 233-1336
Email: Elana.Ferrari@edelman.com

Click Here for More Information »

Cutting edge therapy for Psoriasis patients now available in the Caribbean

- Clinical trials with over 3,000 treated patients demonstrate its efficacy.

- Studies demonstrated that at least two thirds of the patients obtained 75% improvement of Psoriasis Activity Severity Index.

- This treatment significantly improves the quality of life of patients with moderate to severe plaque psoriasis.

PANAMA CITY, Dec. 2, 2015 /PRNewswire-HISPANIC PR WIRE/ – Psoriasis is a chronic skin disease that affects around 140 million people worldwide.  It’s more frequent between the ages of 15 and 25, but may develop at any age and highly impacts the quality of life.

Several types of psoriasis exist, which range from mild to severe and disabling. Plaque psoriasis is the most common form and is known for producing inflammation and scaly patches of thickened skin called “plaques”. It is caused due to a problem in the immunologic system, where white blood cells that normally become activated to fight infections, are in this case activated against the healthy skin cells.  The cause of the disease is unknown. The immunologic system is activated and produces inflammatory mediators which are responsible for the skin lesions.

During this process, white blood cells release chemical products called “cytokines”, which produce inflammation, reddening of the skin and make the cutaneous cells move from deeper skin layer to surface at a higher speed than normal, (almost 5 times). These cells accumulate and generate the scaly patches. Psoriatic lesions show the aspect of scales, sometimes with a white silver color, while the skin below is red and if scratched it can bleed. Two specific cytokines are increased in the pathogenesis of psoriasis and produce the inflammatory process of the disease (Interleukin 12 and Interleukin 23).

Ustekinumab is a monoclonal antibody that represents the first of a new class of psoriasis therapies that specifically and selectively targets IL-12/IL-23.

Ustekinumab is now available in the Caribbean, specifically in Aruba, Bahamas, Bermuda, Cayman Islands, Curacao and Jamaica.[i] Ustekinumab is commercialized under the brand Stelara™.

This therapeutic alternative is the latest generation of psoriasis treatment. With over 3,000 treated patients (in clinical trials) up to 5 years of treatment. The data obtained proves that the treatment is well tolerated and safe.

Clinical trials demonstrated that at least two thirds of the patients obtained a 75% improvement of the psoriasis, in accordance with the Psoriasis Activity Severity Index (PASI 75), after only two doses of Ustekinumab. This innovative treatment has a very convenient dosage regimen when compared with other biological therapies for psoriasis. After 5 years, approximately 80% of the patients treated with Ustekinumab maintain response.

Until recent years, psoriasis was considered a disease limited to the skin. Recent evidence, from important population studies in psoriatic patients, has demonstrated an increase in mortality and a decrease in life expectancy between 3 to 4 years in patients with psoriasis.

On the other hand, the impact of psoriasis notably influences the quality of life, and this is reflected in the increase of different social and psychoactive pathologies, and in the acquisition of unhealthy habits like tobacco and alcohol, favored by low self-esteem, anxiety, depression and the isolation which patients feel subjected to.[ii]

“Ustekinumab significantly improves the quality of life of patients with moderate to severe psoriasis, as well as their physical and mental functions. After 12 weeks of treatment, patients treated with Ustekinumab present a significant improvement in their mental well-being and their physical condition”, affirmed Dr. Eduardo Franco; Janssen’s Medical Director for Central America and the Caribbean.

The itching and pain, the plaques in their hands and feet may hinder the performance of certain tasks or participation in some activities. Overtime, about 40% of psoriatic patients develop arthritis. “The most severe cases of psoriasis may even generate immobility of the patient. Some patients compare the reduction of their physical activities to the ones generated by other diseases as cancer or heart diseases”, pointed out Dr. Jose Antonio Herrera, Immunology Medical Manager for Janssen.

About Janssen

Janssen is a Company dedicated to the research of providing innovative products that help protect and improve the life of people, and face and solve the most important and unresolved medical needs of our times, in the areas of oncology, immunology, neurosciences and infectious, cardiovascular and metabolic diseases.

Across the different companies of the Johnson & Johnson group, our people are united in the passionate pursuit of solutions through science, in benefit of the patients.

Present in over 50 countries, we share the commitment of the founders of the Company, of innovating in ideas, products and services for the patients of the whole world.

[i] Ustekinumab was approved by the following Health Authorities:
Aruba: Drug Registration Board,
Curacao; Drug Registration Board
Jamaica: Ministry of Health.
Cayman Islands, Bahamas and Bermuda are not regulated countries.

[ii] 2009 Latin American Psoriasis Consensus, treatment guides, Latin American Psoriasis Society

Fact Sheet Psoriasis

  1. Psoriasis is a chronic disease that affects over 140 million people worldwide.
  2. It presents itself more frequently between the ages of 15 and 25, but may develop at any age and highly impacts the quality of life.
  3. The main cause for this disease is unknown. The immunologic system is activated and produces inflammatory mediators which stimulated white cells and infiltrate the skin layers. The deep layer cells move to the outer layer of the skin at least 5 time faster than usual, and this produces the characteristic plaque of the psoriasis.
  4. There are several clinical forms of the disease, plaque psoriasis being the most common form. It is known for producing inflammation and scaly patches of thickened skin called “plaques”.
  5. Moderate to severe plaque psoriasis, notably influences the quality of life.  Severe cases of psoriasis may even generate immobility of the patient.
  6. Some patients compare the reduction of their physical activities to the ones generated by other diseases such as cancer or heart disease.
  7. Ustekinumab is now available in the Caribbean, specifically in Aruba, Bahamas, Bermuda, Caiman Islands, Curacao and Jamaica.[i]  Ustekinumab is commercialized under the brand Stelara™.
  8. Clinical trials with over 3,000 patients treated with Ustekinumab have demonstrated its efficacy. At least two thirds of the patients obtained a 75% improvement of the Psoriasis Activity Severity Index.
  9. After 5 years, approximately 80% of the patients treated with Ustekinumab maintain response.

[i] Ustekinumab was approved by the following Health Authorities:
Aruba: Drug Registration Board,
Curacao; Drug Registration Board
Jamaica: Ministry of Health.
Cayman Islands, Bahamas and Bermuda are not regulated countries.

CONTACT:  Janssen, JoanTownsend, (507) 64306252 or (507) 3989740, tojoa

Click Here for More Information »